CA3024012A1 - Crenolanib for treating flt3 mutated proliferative disorders associated mutations - Google Patents
Crenolanib for treating flt3 mutated proliferative disorders associated mutations Download PDFInfo
- Publication number
- CA3024012A1 CA3024012A1 CA3024012A CA3024012A CA3024012A1 CA 3024012 A1 CA3024012 A1 CA 3024012A1 CA 3024012 A CA3024012 A CA 3024012A CA 3024012 A CA3024012 A CA 3024012A CA 3024012 A1 CA3024012 A1 CA 3024012A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- crenolanib
- flt3
- cancer
- chromosomal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416475P | 2016-11-02 | 2016-11-02 | |
| US62/416,475 | 2016-11-02 | ||
| PCT/US2017/059377 WO2018085292A1 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
| US15/799,684 | 2017-10-31 | ||
| US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3024012A1 true CA3024012A1 (en) | 2018-05-11 |
Family
ID=62020370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3024012A Pending CA3024012A1 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11078541B2 (https=) |
| EP (1) | EP3359155A4 (https=) |
| JP (3) | JP2019532011A (https=) |
| KR (2) | KR20200079351A (https=) |
| CN (1) | CN108778276A (https=) |
| AU (1) | AU2017353925A1 (https=) |
| BR (1) | BR112019008762A2 (https=) |
| CA (1) | CA3024012A1 (https=) |
| CL (1) | CL2019001208A1 (https=) |
| CO (1) | CO2019005466A2 (https=) |
| EA (1) | EA201991078A1 (https=) |
| HK (1) | HK1257195A1 (https=) |
| IL (1) | IL266303A (https=) |
| MX (1) | MX2019005008A (https=) |
| PE (1) | PE20191238A1 (https=) |
| PH (1) | PH12019500965A1 (https=) |
| SG (1) | SG11201903889TA (https=) |
| WO (1) | WO2018085292A1 (https=) |
| ZA (1) | ZA201903089B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12534764B2 (en) | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| BR112019008762A2 (pt) | 2016-11-02 | 2019-07-16 | Arog Pharmaceuticals, Inc. | método para o tratamento de um distúrbio proliferativo mutado em flt3 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| EP3856173A4 (en) * | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS |
| CN109678849A (zh) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | 一种抗癌药物的制备方法 |
| US11471451B2 (en) * | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN110531016B (zh) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | 一种hyml-122血药浓度定量分析方法 |
| JP2023536068A (ja) * | 2020-07-20 | 2023-08-23 | アログ・ファーマシューティカルズ・インコーポレイテッド | クレノラニブの結晶形態およびそれを用いる方法 |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| CN112921091B (zh) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| JP2023063189A (ja) * | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| CN115141886B (zh) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| AU2002226877B2 (en) | 2000-10-17 | 2006-01-12 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| ES2269793T3 (es) | 2001-10-30 | 2007-04-01 | Novartis Ag | Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3. |
| ATE302771T1 (de) | 2001-12-27 | 2005-09-15 | Theravance Inc | Indolinon-derivative als protein-kinasehemmer |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| AU2003280599A1 (en) | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| AU2003290699B2 (en) | 2002-11-13 | 2009-08-27 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| DK1641780T3 (da) | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| US8999638B2 (en) * | 2009-04-06 | 2015-04-07 | Vanda Pharmaceuticals, Inc. | Method of treatment based on polymorphisms of the KCNQ1 gene |
| JP2015512630A (ja) * | 2012-03-12 | 2015-04-30 | メモリアル スローン−ケタリング キャンサー センター | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| BR112019008762A2 (pt) | 2016-11-02 | 2019-07-16 | Arog Pharmaceuticals, Inc. | método para o tratamento de um distúrbio proliferativo mutado em flt3 |
-
2017
- 2017-10-31 BR BR112019008762-1A patent/BR112019008762A2/pt not_active Application Discontinuation
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/es unknown
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/es unknown
- 2017-10-31 EA EA201991078A patent/EA201991078A1/ru unknown
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en not_active Ceased
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/ko not_active Ceased
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/zh active Pending
- 2017-10-31 HK HK18116172.6A patent/HK1257195A1/zh unknown
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/ja active Pending
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/ko not_active Ceased
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/es unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/es unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US12404555B2/en active Active
-
2022
- 2022-03-02 JP JP2022031616A patent/JP7536320B2/ja active Active
-
2024
- 2024-04-11 JP JP2024064106A patent/JP2024096859A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,777 patent/US20250305063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1257195A1 (zh) | 2019-10-18 |
| WO2018085292A1 (en) | 2018-05-11 |
| EA201991078A1 (ru) | 2019-11-29 |
| JP2022071099A (ja) | 2022-05-13 |
| IL266303A (en) | 2019-06-30 |
| US20210324481A1 (en) | 2021-10-21 |
| US11078541B2 (en) | 2021-08-03 |
| BR112019008762A2 (pt) | 2019-07-16 |
| US20250305063A1 (en) | 2025-10-02 |
| CN108778276A (zh) | 2018-11-09 |
| US20180117031A1 (en) | 2018-05-03 |
| SG11201903889TA (en) | 2019-05-30 |
| CO2019005466A2 (es) | 2019-07-31 |
| US12404555B2 (en) | 2025-09-02 |
| MX2019005008A (es) | 2019-09-10 |
| JP2019532011A (ja) | 2019-11-07 |
| KR20180074792A (ko) | 2018-07-03 |
| ZA201903089B (en) | 2019-12-18 |
| JP2024096859A (ja) | 2024-07-17 |
| JP7536320B2 (ja) | 2024-08-20 |
| PH12019500965A1 (en) | 2019-12-02 |
| CL2019001208A1 (es) | 2019-07-26 |
| AU2017353925A1 (en) | 2018-09-27 |
| PE20191238A1 (es) | 2019-09-11 |
| EP3359155A1 (en) | 2018-08-15 |
| KR20200079351A (ko) | 2020-07-02 |
| EP3359155A4 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404555B2 (en) | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | |
| US12171757B2 (en) | Crenolanib for treating FLT3 mutated proliferative disorders | |
| US20240229156A1 (en) | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles | |
| US20140194442A1 (en) | Anticancer therapy | |
| US12534764B2 (en) | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | |
| US20210145823A1 (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| OA19291A (en) | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations. | |
| US20220218694A1 (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| WO2021255518A1 (en) | Compositions and methods for treating acute myeloid leukemia | |
| OA18036A (en) | Crenolanib for treating FLT3 mutated proliferative disorders. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221031 |